Skip to main content
SpringerLink
Log in

Antibacterials/atezolizumab/bevacizumab

Alterations in microbial composition of gut microbiota and lack of efficacy: 19 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Maesaka K, et al. Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. PLOS One 18: e0281459, No. 2, Jan 2023. Available from: URL: http://doi.org/10.1371/journal.pone.0281459

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antibacterials/atezolizumab/bevacizumab. Reactions Weekly 1954, 38 (2023). https://doi.org/10.1007/s40278-023-37856-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-37856-x

Search

Navigation